Answers are grounded in this paper and cite their sources.
Assesses diagnostic and co-management gaps in metastatic castration-resistant prostate cancer treatment, suggesting urgent need for equitable access.
e17038 Background: the management of metastatic castration-resistant prostate cancer (mCRPC) is increasingly complex, demanding greater multidisciplinary collaboration and reliance on advanced diagnostics. This study quantifies the real-world evolution of co-management, patient risk profiles, and diagnostic testing patterns between US academic and community settings. Methods: data were extracted from the Ipsos Global Oncology Monitor. We analyzed two consecutive 12-month cohorts of US mCRPC patients on active systemic therapy: 791 patients from Aug '23-Sep '24 and 645 from Aug '24-Sep '25. A year-over-year comparative analysis of patient characteristics, co-management rates, and diagnostic utilization was performed, stratifying by specialty (Oncology vs. Urology) and practice type (Academic vs. Community). Results: a significant trend towards multidisciplinary care was observed, with overall co-management increasing from 32% to 43% (p < 0.01). This growth was driven exclusively by the academic setting, which saw a threefold increase (18% to 64%; p < 0.01), while the community setting remained stable at 36%. This occurred even as community practices managed a higher-risk patient population, characterized by a dual burden of both more aggressive disease biology (67% vs. 48% with Gleason score 8-10; p < 0.01) and a greater prevalence of significant comorbidities (e.g., hypertension 70% vs. 41% p < 0.01; cardiovascular disease 25% vs. 15%; p < 0.01). Concurrently, the gap in PSMA-PET utilization between Oncologists/Heam Oncs (increasing from 60% to 80%) and Urologists (stationary at ~55-58%) widened significantly. This diagnostic disparity is also correlated with regimen choice, with Urologists favoring more often hormonal-only regimens linked to less frequent (quarterly) PSA testing. Conclusions: The mCRPC treatment landscape is rapidly consolidating around a co-management model, but this evolution is primarily confined to the academic setting, likely due to the infrastructure required for complex novel therapies. A concerning and widening gap in the adoption of PSMA-PET imaging persists, with urologists lagging significantly behind oncologists. This diagnostic disparity creates a critical barrier to care, as it may limit access to PSMA-targeted therapies for the higher-risk population predominantly managed in the community. These findings highlight an urgent need for educational and system-level changes to harmonize the application of advanced diagnostics and ensure equitable access to modern, evidence-based mCRPC care across all practice settings.
No takes yet. Share an insight, caveat, or question.
Franceschetti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: